Cardio Oncology and Heart Failure - Cardiovascular Update

European Society of Cardiology Core Curriculum for cardio?oncology

European Journal of Heart Failure

DECEMBER 20, 2023

Abstract Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases.

Cardio Oncology

Cardio Oncology Cancer Certification Document

Sleep Apnea Prevalence in Cardio-Oncology Patients Similar to Other Risk Factors

HCPLive

FEBRUARY 13, 2024

Sleep apnea prevalence in cardiology patients was similar to the rates in patients with heart failure., and sleep apnea prevalence in cardio-oncology patients was the same or greater than other traditional risk factors.

Cardio Oncology

Cardio Oncology Risk Factors Heart Failure

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure

MARCH 11, 2025

Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer.

Cardio Oncology

Cardio Oncology Heart Failure Cancer

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Heart Failure Society of America issues cardio-oncology guidance: 5 things to know

Becker's Hospital Review - Cardiology

OCTOBER 17, 2024

The Heart Failure Society of America has released a scientific statement outlining its insights on the link between heart failure and cancer, the two leading causes of mortality and morbidity in the U.S. 15 in the Journal of Cardiac Failure. The statement was published Oct.

Cardio Oncology

Cardio Oncology Heart Failure Cancer

Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain

Frontiers in Cardiovascular Medicine

JANUARY 19, 2024

The baseline risk of CTRCD was graded according to the risk score proposed by the Heart Failure Association (HFA) Cardio-Oncology Working Group and the International Cardio-Oncology Society (ICOS). CTRCD and its severity were defined according to the current European Society of Cardiology (ESC) guidelines.

Cardio Oncology

Cardio Oncology Cancer Heart Failure Risk Factors

Top Cardiology Conferences in 2024

Cardiology Update

JANUARY 2, 2024

Heart Failure 2024 Date: May 11-14, 2024 Location: Lisbon, Portugal and online Overview: The Heart Failure Congress stands as the premier global gathering encompassing the full spectrum of heart failure. Hashtag: #ESCPrev2024 5. Hashtag: #HeartFailure2024 6.

Heart Failure

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology

Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis

Open Heart

AUGUST 22, 2022

Patients with recurrent or advanced-stage breast cancer, with a history of heart failure, receiving neoadjuvant chemotherapy or a preoperative history of less than 6 months were excluded. Women with breast cancer who underwent initial surgery were included. Results We identified 12 060 eligible patients (mean age 50.8±8.56

Cardio Oncology

Cardio Oncology Cancer Heart Failure Risk Factors

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24

DAIC

APRIL 3, 2024

24 is guided by prominent clinicians and leaders, and focuses on important fundamentals in managing and treating heart conditions. This includes a review of updated clinical guidelines and best practices. Each session is interactive and includes knowledge check-ins and dedicated time for discussion. 24 news here.

Education

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology

Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review

Frontiers in Cardiovascular Medicine

JUNE 6, 2024

Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy.

Tachycardia

Tachycardia Cancer Cardio Oncology Arrhythmia

AHA 2023 Highlights

Cardiology Update

DECEMBER 3, 2023

Chadi Alraies discusses highlights from the American Heart Association (AHA) Scientific Sessions 2023, which were held in Philadelphia, Pennsylvania (PA), on November 11-13, 2023. There were many important developments in presented in key clinical trial presentations and publications stemming from the AHA Scientific Sessions 2023.

Research

Research Cardio Oncology COVID-19 Heart Failure

Results Involving Philips FDA-cleared AI-enabled Cardiovascular Ultrasound Platform to be Presented at American Society of Echocardiography Scientific Sessions, ASE 2024

DAIC

JUNE 12, 2024

The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds.

Ultrasound

Ultrasound Cardio Oncology Technology Congenital Heart Disease

Long-term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should be Lower

DAIC

FEBRUARY 28, 2024

The findings – published this week in the Journal of the American College of Cardiology — could fuel advocacy for a paradigm shift in clinical heart health guidelines to address cardiovascular risk factors at an earlier age in childhood cancer survivors.

Risk Factors

Risk Factors Cancer Cardio Oncology Blood Pressure

Highlights of ACC 2024

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI).

Angina

Angina Myocardial Infarction Aortic valve Coronary Artery Disease

European Society of Cardiology Core Curriculum for cardio?oncology

Sleep Apnea Prevalence in Cardio-Oncology Patients Similar to Other Risk Factors

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

Webinars

Heart Failure Society of America issues cardio-oncology guidance: 5 things to know

Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain

Top Cardiology Conferences in 2024

Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24

Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review

AHA 2023 Highlights

Results Involving Philips FDA-cleared AI-enabled Cardiovascular Ultrasound Platform to be Presented at American Society of Echocardiography Scientific Sessions, ASE 2024

Long-term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should be Lower

Highlights of ACC 2024

Stay Connected